PNC Financial Services Group Inc. Sells 6,775 Shares of Zoetis Inc. $ZTS

PNC Financial Services Group Inc. lowered its stake in Zoetis Inc. (NYSE:ZTS) by 2.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 268,392 shares of the company’s stock after selling 6,775 shares during the period. PNC Financial Services Group Inc. owned approximately 0.06% of Zoetis worth $41,856,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Lindbrook Capital LLC increased its stake in Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares during the period. Scott & Selber Inc. grew its holdings in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after purchasing an additional 67 shares during the last quarter. Secure Asset Management LLC increased its stake in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after buying an additional 68 shares during the period. Moment Partners LLC raised its holdings in Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after buying an additional 72 shares during the last quarter. Finally, CVA Family Office LLC boosted its position in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after buying an additional 74 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $121.04 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $117.26 and a one year high of $181.85. The company has a 50-day simple moving average of $141.57 and a two-hundred day simple moving average of $151.73. The firm has a market capitalization of $53.34 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the business earned $1.58 EPS. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. BTIG Research cut their target price on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Argus reiterated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average target price of $180.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.